EA201591703A1 - Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина - Google Patents

Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина

Info

Publication number
EA201591703A1
EA201591703A1 EA201591703A EA201591703A EA201591703A1 EA 201591703 A1 EA201591703 A1 EA 201591703A1 EA 201591703 A EA201591703 A EA 201591703A EA 201591703 A EA201591703 A EA 201591703A EA 201591703 A1 EA201591703 A1 EA 201591703A1
Authority
EA
Eurasian Patent Office
Prior art keywords
halogen
alkyl
ababilities
substituted
compounds
Prior art date
Application number
EA201591703A
Other languages
English (en)
Other versions
EA029276B1 (ru
Inventor
Кристин Ф. Желен
Терри П. Леболд
Брок Т. Шайрман
Джинни М. Зифф
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201591703A1 publication Critical patent/EA201591703A1/ru
Publication of EA029276B1 publication Critical patent/EA029276B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Изобретение относится к соединениям формулы Iгде X представляет собой N или CR; Y представляет собой N или CR; Rпредставляет собой Н, алкокси, галоген, триазолил, пиримидинил, оксазолил, изоксазол, оксадиазолил или пиразолил; Rпредставляет собой Н, алкил, алкокси или галоген; Z представляет собой NH или О; Rпредставляет собой Н, алкил, алкокси, галоген или триазолил; Rпредставляет собой Н или алкил; или Rи Rвместе с атомами, к которым они присоединены, формируют 6-членное арильное кольцо или 5- или 6-членное гетероарильное кольцо; Rпредставляет собой пиридил, пиразинил или пиримидинил, причем пиридил, пиразинил или пиримидинил необязательно замещен галогеном или алкилом; n равно 1 или 2. Также описаны способы получения соединений формулы I. Изобретение также относится к фармацевтическим композициям, содержащим соединения формулы I. Способы применения соединений настоящего изобретения также входят в объем настоящего изобретения.
EA201591703A 2013-03-13 2014-03-12 Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина EA029276B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780378P 2013-03-13 2013-03-13
PCT/US2014/024293 WO2014165070A1 (en) 2013-03-13 2014-03-12 Substituted 2-azabicycles and their use as orexin receptor modulators

Publications (2)

Publication Number Publication Date
EA201591703A1 true EA201591703A1 (ru) 2016-02-29
EA029276B1 EA029276B1 (ru) 2018-03-30

Family

ID=50487148

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591703A EA029276B1 (ru) 2013-03-13 2014-03-12 Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина

Country Status (38)

Country Link
US (5) US8969352B2 (ru)
EP (4) EP3363438B1 (ru)
JP (1) JP6275815B2 (ru)
KR (1) KR102209424B1 (ru)
CN (3) CN108864093A (ru)
AR (1) AR095423A1 (ru)
AU (2) AU2014248680B2 (ru)
BR (1) BR112015022294B1 (ru)
CA (1) CA2904618C (ru)
CL (1) CL2015002609A1 (ru)
CR (2) CR20210523A (ru)
CY (3) CY1120024T1 (ru)
DK (2) DK2970314T3 (ru)
EA (1) EA029276B1 (ru)
ES (3) ES2760564T3 (ru)
HK (1) HK1219725A1 (ru)
HR (3) HRP20230633T1 (ru)
HU (3) HUE036193T2 (ru)
IL (2) IL240466B (ru)
JO (1) JOP20140092B1 (ru)
LT (2) LT3363438T (ru)
ME (2) ME03572B (ru)
MX (2) MX368466B (ru)
MY (1) MY183725A (ru)
NI (1) NI201500130A (ru)
NO (1) NO3107630T3 (ru)
PE (1) PE20151599A1 (ru)
PH (1) PH12015501929B1 (ru)
PL (3) PL3363438T3 (ru)
PT (2) PT3363438T (ru)
RS (3) RS59466B1 (ru)
SG (1) SG11201507415QA (ru)
SI (2) SI3363438T1 (ru)
TW (1) TWI621618B (ru)
UA (1) UA118669C2 (ru)
UY (1) UY35409A (ru)
WO (1) WO2014165070A1 (ru)
ZA (1) ZA201507562B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101859400B1 (ko) 2009-10-23 2018-05-18 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
AU2015226679B2 (en) 2014-03-06 2017-05-25 Shanghai Haiyan Pharmaceutical Technology Co. Ltd Piperidine derivatives as orexin receptor antagonist
AU2015314851B2 (en) * 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9938276B2 (en) * 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016295693B2 (en) 2015-07-17 2020-05-21 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
CN107709318B (zh) * 2015-08-14 2020-09-25 上海海雁医药科技有限公司 食欲素受体拮抗剂受体化合物的制备方法及其中间体和晶型
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA3005918C (en) 2015-11-23 2023-10-17 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
LT3426251T (lt) 2016-03-10 2022-06-27 Janssen Pharmaceutica Nv Depresijos gydymo būdai, panaudojant oreksino-2 receptoriaus antagonistus
EP3730487B1 (en) 2016-06-13 2022-04-27 Gilead Sciences, Inc. Azetidine derivatives as fxr (nr1h4) modulators
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP7258748B2 (ja) 2016-11-22 2023-04-17 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
EP3676261A1 (en) * 2017-09-01 2020-07-08 Chronos Therapeutics Limited Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
AU2019395255A1 (en) * 2018-12-14 2021-05-06 Dana-Farber Cancer Institute, Inc. Pyrazolopyridine inhibitors of c-Jun-N-terminal kinases and uses thereof
EP4360632A2 (en) 2019-01-15 2024-05-01 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
AU2020225225B2 (en) 2019-02-19 2022-12-22 Gilead Sciences, Inc. Solid forms of FXR agonists

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674793A (en) 1967-03-29 1972-07-04 Sterling Drug Inc 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en) 2001-04-11 2003-01-14 Bethlehem Steel Corporation Method and apparatus for forming deep-drawn articles
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
WO2004069816A1 (en) 2003-02-07 2004-08-19 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
CA2516329A1 (en) 2003-02-21 2004-09-02 Pharmacia & Upjohn Company Llc Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them
CA2627630A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
CA2663113A1 (en) 2006-09-11 2008-03-20 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
ATE496043T1 (de) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
EP2150115B1 (en) 2007-05-23 2013-09-18 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
NZ582664A (en) 2007-07-17 2012-03-30 Bristol Myers Squibb Co Pyridone gpr119 g protein-coupled receptor agonists
EP2234999A1 (en) 2007-12-21 2010-10-06 F. Hoffmann-La Roche AG Heteroaryl derivatives as orexin receptor antagonists
RU2010138640A (ru) * 2008-02-21 2012-03-27 Актелион Фармасьютиклз Лтд (Ch) Производные 2-аза-бицикло [2.2.1] гептана
WO2009133522A1 (en) 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
EP2350061B1 (en) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
JP2012506375A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
EP2370426A1 (en) 2008-12-02 2011-10-05 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
WO2010122151A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
JP5847087B2 (ja) * 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
US9062044B2 (en) 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
KR101859400B1 (ko) 2009-10-23 2018-05-18 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
EP2493307B1 (en) 2009-10-29 2016-04-27 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
CA2781390A1 (en) 2009-12-14 2011-06-23 Inspire Pharmaceuticals, Inc. Bridged bicyclic rho kinase inhibitor compounds, composition and use
US8697691B2 (en) 2009-12-21 2014-04-15 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130096141A1 (en) 2010-06-18 2013-04-18 Bernard R. Neustadt Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9546152B2 (en) 2012-10-23 2017-01-17 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
WO2014075392A1 (en) 2012-11-16 2014-05-22 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
SG11201606367YA (en) 2014-02-06 2016-09-29 Abbvie Inc 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators

Also Published As

Publication number Publication date
HUE047592T2 (hu) 2020-05-28
NI201500130A (es) 2015-11-30
CY1122392T1 (el) 2021-01-27
HRP20192032T1 (hr) 2020-02-07
WO2014165070A1 (en) 2014-10-09
CN110669052A (zh) 2020-01-10
US9845333B2 (en) 2017-12-19
CR20150433A (es) 2015-10-26
MX361529B (es) 2018-12-07
RS64551B1 (sr) 2023-10-31
PL2970314T3 (pl) 2018-05-30
CY1126106T1 (el) 2023-11-15
EP2970314B1 (en) 2017-12-13
CN105308048B (zh) 2019-10-08
EP4272824A2 (en) 2023-11-08
ES2659397T3 (es) 2018-03-15
IL264606A (en) 2019-02-28
EP2970314A1 (en) 2016-01-20
US10183953B2 (en) 2019-01-22
NO3107630T3 (ru) 2018-01-06
HRP20230633T1 (hr) 2023-09-29
ME03572B (me) 2020-07-20
MY183725A (en) 2021-03-10
UA118669C2 (uk) 2019-02-25
UY35409A (es) 2014-09-30
PH12015501929A1 (en) 2016-01-04
HUE063608T2 (hu) 2024-01-28
ME03011B (me) 2018-10-20
NZ710872A (en) 2020-10-30
JP6275815B2 (ja) 2018-02-07
US20140275118A1 (en) 2014-09-18
MX2015011815A (es) 2016-11-07
LT2970314T (lt) 2018-02-12
US20160052939A1 (en) 2016-02-25
JOP20140092B1 (ar) 2021-08-17
HUE036193T2 (hu) 2018-06-28
IL240466A0 (en) 2015-09-24
CR20210523A (es) 2021-11-19
PE20151599A1 (es) 2015-11-12
AU2018204835A1 (en) 2018-07-19
AU2014248680A1 (en) 2015-08-27
LT3363438T (lt) 2019-11-11
SI2970314T1 (en) 2018-02-28
ES2950032T3 (es) 2023-10-04
SG11201507415QA (en) 2015-10-29
BR112015022294A2 (pt) 2017-07-18
DK2970314T3 (en) 2018-02-26
EP3622956C0 (en) 2023-06-07
EP3622956A1 (en) 2020-03-18
AU2014248680B2 (en) 2018-07-26
CA2904618C (en) 2021-12-07
IL240466B (en) 2019-03-31
PT3363438T (pt) 2019-12-11
EP3622956B9 (en) 2023-09-27
PT2970314T (pt) 2018-03-05
KR20150126694A (ko) 2015-11-12
AU2018204835B2 (en) 2019-08-08
US8969352B2 (en) 2015-03-03
US20150174129A1 (en) 2015-06-25
ZA201507562B (en) 2019-04-24
CN110669052B (zh) 2022-10-11
KR102209424B1 (ko) 2021-01-29
CL2015002609A1 (es) 2016-03-28
AR095423A1 (es) 2015-10-14
CN108864093A (zh) 2018-11-23
CN105308048A (zh) 2016-02-03
US20170204096A1 (en) 2017-07-20
EA029276B1 (ru) 2018-03-30
EP3363438B1 (en) 2019-09-18
CA2904618A1 (en) 2014-10-09
DK3363438T3 (da) 2019-11-11
EP4272824A3 (en) 2024-01-10
BR112015022294B1 (pt) 2022-09-13
EP3622956B1 (en) 2023-06-07
US9447117B2 (en) 2016-09-20
ES2760564T3 (es) 2020-05-14
PL3363438T3 (pl) 2020-02-28
PH12015501929B1 (en) 2016-01-04
US20170015651A1 (en) 2017-01-19
JP2016512535A (ja) 2016-04-28
TW201446757A (zh) 2014-12-16
PL3622956T3 (pl) 2023-09-18
CY1120024T1 (el) 2018-12-12
MX368466B (es) 2019-10-03
SI3363438T1 (sl) 2019-11-29
TWI621618B (zh) 2018-04-21
HRP20180303T1 (hr) 2018-03-23
US9611277B2 (en) 2017-04-04
RS56875B1 (sr) 2018-04-30
HK1219725A1 (zh) 2017-04-13
RS64551B9 (sr) 2023-12-29
RS59466B1 (sr) 2019-11-29
EP3363438A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
EA201591703A1 (ru) Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина
EA201591675A1 (ru) Замещенные 7-азабициклы и их применение в качестве модуляторов рецепторов орексина
EA201591429A1 (ru) 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена
AR100645A1 (es) Derivados de pirazolo-pirimidina
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
MY192641A (en) Novel pyrimidine and pyridine compounds and their usage
JO3509B1 (ar) معدلات p2x7
MX2015015786A (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il) arilcarboxamida sustituidos y su uso como herbicidas.
AR115662A2 (es) Derivados de piperidina
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
PL401473A1 (pl) Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania
SA519400868B1 (ar) معدلات عطرية غير متجانسة لأشعة جاما لمستقبل يتيم ذي علاقة بريتينويد
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
BR112015028871A2 (pt) novos compostos de 3,4-dihidro-2h-isoquinolina-1-ona e 2,3-dihidro-isoindol-1-ona
MX368759B (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
UA107357C2 (ru) Производные (6-оксо-1,6-дигидропиримидин-2-ил)амида, их получение и их фармацевтическое применение в качестве ингибиторов фосфорилирования акт (ркв)
BR112015029696A2 (pt) novos compostos de 3,4-dihidro-2h-isoquinolina-1-ona e de 2,3-dihidro-isoindol-1-ona